According to DelveInsight, the Stress Urinary Incontinence (SUI) pipeline includes over 10 leading companies actively developing more than 10 therapeutic candidates for the treatment of SUI.
Stress urinary incontinence Overview:
Stress Urinary Incontinence (SUI) is a prevalent and often distressing condition characterized by the involuntary leakage of urine during activities that increase abdominal pressure, such as coughing, sneezing, or exercising. It predominantly affects women, with factors such as childbirth, menopause, and weakened pelvic floor muscles contributing to its development. SUI can have a significant impact on daily life, causing embarrassment, social withdrawal, and diminished self-confidence.
The causes of SUI are multifactorial, involving various anatomical, physiological, and functional impairments. Key factors include weakness of the bladder neck and urethra, often due to pelvic floor muscle weakness and urethral sphincter dysfunction. Urethral hypermobility, in which the bladder neck and urethra shift out of place under pressure, further aggravates the condition. Additionally, inadequate urethral support and neuromuscular or mechanical dysfunction of the striated urethral sphincter contribute to urine leakage. Understanding these underlying mechanisms is crucial for effective treatment and management of SUI.
Request for a detailed insights report on Stress urinary incontinence pipeline insights
"Stress urinary incontinence Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Stress urinary incontinence Therapeutics Market.
Key Takeaways from the Stress urinary incontinence Pipeline Report
-
DelveInsight’s Stress Urinary Incontinence (SUI) pipeline report highlights an active landscape, with over 10 companies developing more than 10 therapeutic candidates for SUI treatment.
-
Key players—including Innovacell Biotechnologie GmbH, Versameb AG, Taiho Pharmaceutical, Cook MyoSite, Mapi Pharma, and others—are exploring new therapies aimed at improving the SUI treatment landscape. Notable pipeline candidates in various stages of development include VMB-100, ICES13, among others.
-
In May 2024, Watkins-Conti received FDA 510(k) clearance for Yōni.Fit, a non-surgical, self-care device designed to manage SUI in women. Made entirely from medical-grade silicone, Yōni.Fit provides an innovative, non-invasive option for SUI management.
Stress urinary incontinence Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Stress urinary incontinence Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stress urinary incontinence treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Stress urinary incontinence market.
Download our free sample page report on Stress urinary incontinence pipeline insights
Stress urinary incontinence Emerging Drugs
-
ICES13: Innovacell Biotechnologie GmbH
-
VMB-100: Versameb AG
Stress urinary incontinence Companies
Over 10 leading companies are actively developing therapies for Stress Urinary Incontinence, with Innovacell Biotechnologie GmbH having a drug candidate that has reached the most advanced stage of development, Phase III.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Stress urinary incontinence pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Stress urinary incontinence Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Stress urinary incontinence Therapies and Key Companies: Stress urinary incontinence Clinical Trials and advancements
Stress urinary incontinence Pipeline Therapeutic Assessment
• Stress urinary incontinence Assessment by Product Type
• Stress urinary incontinence By Stage
• Stress urinary incontinence Assessment by Route of Administration
• Stress urinary incontinence Assessment by Molecule Type
Download Stress urinary incontinence Sample report to know in detail about the Stress urinary incontinence treatment market @ Stress urinary incontinence Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Stress urinary incontinence Current Treatment Patterns
4. Stress urinary incontinence - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Stress urinary incontinence Late-Stage Products (Phase-III)
7. Stress urinary incontinence Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Stress urinary incontinence Discontinued Products
13. Stress urinary incontinence Product Profiles
14. Stress urinary incontinence Key Companies
15. Stress urinary incontinence Key Products
16. Dormant and Discontinued Products
17. Stress urinary incontinence Unmet Needs
18. Stress urinary incontinence Future Perspectives
19. Stress urinary incontinence Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Stress urinary incontinence Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
